Designing rational therapies for multiple sclerosis.
Steinman
L
L
Neurocrine Biosciences, San Diego, CA, USA.
Conlon
P
P
D018849:Controlled Clinical Trials as Topic; D004198:Disease Susceptibility; D005260:Female; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000037:antagonists & inhibitors / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D017634:Self Tolerance
D006680:HLA Antigens; D004676:Myelin Basic Protein; D010455:Peptides; D011948:Receptors, Antigen, T-Cell; D011994:Recombinant Proteins; C021759:(T,G)-A-L; D016899:Interferon-beta